NELARABINE IN CHILDREN WITH REFRACTORY AND RELAPSED T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

被引：0
|
作者：
Myakova, N. [1 ]
Diakonova, Y. [1 ]
Bydanov, O. [2 ]
Ponomareva, N. [3 ]
Fechina, L. [4 ]
Boychenko, E. [5 ]
Karachunsky, A. [2 ]
Shamardina, A. [6 ]
机构：
[1] Fed Ctr Pediat Hematol Oncol Immunol, Oncohematol, Moscow, Russia
[2] Fed Ctr Pediat Hematol Oncol Immunol, Moscow, Russia
[3] Russian Children Hosp, Moscow, Russia
[4] Ekarinburg Childrens Oncol Ctr, Ekaterinburg, Russia
[5] Med Univ Hosp, St Petersburg, Russia
[6] Reg Chinldren Hosp, Nizhnii Novgorod, Russia
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E876
引用
收藏
页码：349 / 349
页数：1
相关论文
共 50 条
  • [1] Nelarabine for the Treatment of Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
    DeAngelo, Daniel J.
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2009, 23 (05) : 1121 - +
  • [2] Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma
    Candoni, Anna
    Lazzarotto, Davide
    Petruzzellis, Giuseppe
    [J]. EXPERT OPINION ON DRUG SAFETY, 2021, 20 (07) : 751 - 756
  • [3] Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia
    Shimony, Shai
    Liu, Yiwen
    Valtis, Yannis K.
    Paolino, Jonathan D.
    Place, Andrew E.
    Brunner, Andrew M.
    Weeks, Lachelle D.
    Silverman, Lewis B.
    Vrooman, Lynda M.
    Neuberg, Donna S.
    Stone, Richard M.
    DeAngelo, Daniel J.
    Luskin, Marlise R.
    [J]. BLOOD ADVANCES, 2023, 7 (07) : 1092 - 1102
  • [4] Nelarabine Combination Therapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Lymphoma/Leukemia
    Shimony, Shai
    Liu, Yiwen
    Valtis, Yannis K.
    Paolino, Jonathan D.
    Place, Andrew E.
    Brunner, Andrew M.
    Weeks, Lachelle D.
    Silverman, Lewis B.
    Vrooman, Lynda M.
    Neuberg, Donna S.
    Stone, Richard M.
    DeAngelo, Daniel J.
    Luskin, Marlise R.
    [J]. BLOOD, 2022, 140 : 8989 - 8990
  • [5] Nelarabine (Arranon) for T-cell acute lymphoblastic leukemia
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2006, 48 (1228): : 14 - 15
  • [6] Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis
    Kathpalia, Meghavi
    Mishra, Pinki
    Bajpai, Ram
    Bhurani, Dinesh
    Agarwal, Nidhi
    [J]. ANNALS OF HEMATOLOGY, 2022, 101 (08) : 1655 - 1666
  • [7] Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis
    Meghavi Kathpalia
    Pinki Mishra
    Ram Bajpai
    Dinesh Bhurani
    Nidhi Agarwal
    [J]. Annals of Hematology, 2022, 101 : 1655 - 1666
  • [8] Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma
    Samra, Bachar
    Alotaibi, Ahmad S.
    Short, Nicholas J.
    Khoury, Joseph D.
    Ravandi, Farhad
    Garris, Rebecca
    Jain, Nitin
    Konopleva, Marina
    Kantarjian, Hagop
    Jabbour, Elias
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (09) : E245 - E247
  • [9] Outcome of Adults with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
    Samra, Bachar
    Alotaibi, Ahmad S.
    Short, Nicholas
    Khoury, Joseph
    Ravandi, Farhad
    Garris, Rebecca
    Jain, Nitin
    Konopleva, Marina
    Kantarjian, Hagop
    Jabbour, Elie
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S170 - S170
  • [10] The Implication of Dasatinib Treatment in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
    Gocho, Yoshihiro
    [J]. PEDIATRIC BLOOD & CANCER, 2021, 68
12345